OncoMed Pharmaceuticals Inc (OMED):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:OncoMed Pharmaceuticals Inc (OMED) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7576
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
OncoMed Pharmaceuticals Inc (OncoMed) is a clinical-stage biopharmaceutical company focused on discovery and development of novel immuno-oncology (IO) therapeutics for the treatment of cancers. Its pipeline product candidates include navicixizumab, rosmantuzumab, Gitrl-FC Trimer, and anti-TIGIT. OncoMed’s research platform enables to build a portfolio of active therapeutic compounds that target biologic pathways critical for the growth, resistance, recurrence, and metastasis of cancer. The company’s expertise spans across cancer research, drug discovery, clinical development, regulatory affairs, translational medicine and commercial development. The company has strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline for the advancement of its clinical-stage candidates. OncoMed is headquartered in Redwood, California, the US.

OncoMed Pharmaceuticals Inc (OMED) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
OncoMed Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
OncoMed Pharma Partners with Guardant Health 12
OncoMed Pharma Enters Into Co-Development Agreement With Celgene 13
Genomic Health Enters Into Co-Development Agreement With OncoMed Pharma 15
Molecular Response Enters Into Co-Development Agreement With OncoMed Pharma 16
Licensing Agreements 17
Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 17
Equity Offering 18
OncoMed Pharma Plans to Raise USD150 Million in Public Offering of Securities 18
OncoMed Pharma Raises USD4.9 Million in Public offering of Shares 19
OncoMed Pharma Raises USD63.3 Million in Public Offering of Shares 20
OncoMed Pharma Completes IPO Of Shares For US$93.8 Million 22
OncoMed Pharmaceuticals Inc – Key Competitors 24
OncoMed Pharmaceuticals Inc – Key Employees 25
OncoMed Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Aug 02, 2018: OncoMed announces second quarter 2018 financial results and operational highlights 27
May 08, 2018: OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights 29
Mar 08, 2018: OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights 31
Nov 02, 2017: OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights 33
Aug 02, 2017: OncoMed Announces Second Quarter 2017 Financial Results 35
May 08, 2017: OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results 36
Corporate Communications 38
Mar 19, 2018: OncoMed Names John Lewicki As President, CEO And Board Member 38
Jan 04, 2018: OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings has Resigned 39
Nov 27, 2017: OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings to Resume Chairman Responsibilities 40
Apr 24, 2017: OncoMed Announces Workforce Reduction 41
Clinical Trials 42
Jun 12, 2018: OncoMed Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical Trial 42
Apr 18, 2018: OncoMed Presents Preclinical Abstract On anti-TIGIT (OMP-313M32) At The 2018 American Association for Cancer Research Annual Meeting 43
Apr 09, 2018: OncoMed to Present Preclinical Data for OMP-313M32 at the 2018 American Association for Cancer Research Annual Meeting 44
Sep 13, 2017: OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial 45
May 04, 2017: OncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial 46
Apr 05, 2017: OncoMed Announces Presentation on Rosmantuzumab at the American Association for Cancer Research Annual Meeting 2017 47
Apr 05, 2017: OncoMed Highlights Data Presented on GITRL-Fc trimer at the American Association for Cancer Research Annual Meeting 2017 48
Apr 03, 2017: OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017 49
Feb 13, 2017: OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer 51
Jan 04, 2017: OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients 52
Other Significant Developments 53
Jan 04, 2018: OncoMed Provides 2018 Outlook and 2017 Year-End Cash Balance and Announces an Update on the Rosmantuzumab Program 53
Jan 05, 2017: OncoMed Announces Year-End Cash Balance and 2017 Outlook 54
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OncoMed Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
OncoMed Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
OncoMed Pharma Partners with Guardant Health 12
OncoMed Pharma Enters Into Co-Development Agreement With Celgene 13
Genomic Health Enters Into Co-Development Agreement With OncoMed Pharma 15
Molecular Response Enters Into Co-Development Agreement With OncoMed Pharma 16
Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 17
OncoMed Pharma Plans to Raise USD150 Million in Public Offering of Securities 18
OncoMed Pharma Raises USD4.9 Million in Public offering of Shares 19
OncoMed Pharma Raises USD63.3 Million in Public Offering of Shares 20
OncoMed Pharma Completes IPO Of Shares For US$93.8 Million 22
OncoMed Pharmaceuticals Inc, Key Competitors 24
OncoMed Pharmaceuticals Inc, Key Employees 25

List of Figures
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
OncoMed Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[OncoMed Pharmaceuticals Inc (OMED):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pfizer Inc (PFE):医療機器:M&Aディール及び事業提携情報
    Summary Pfizer Inc (Pfizer) is a biopharmaceutical company, which discovers, develops, manufactures and markets healthcare products. It provides medicines, vaccines and consumer healthcare products. The company provides products to treat various conditions including infection, cancer, inflammation, …
  • Perenco Holdings:企業の戦略的SWOT分析
    Perenco Holdings - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Pinnacle West Capital Corporation (PNW):企業の財務・戦略的SWOT分析
    Pinnacle West Capital Corporation (PNW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Sevion Therapeutics Inc (SVON)-製薬・医療分野:企業M&A・提携分析
    Summary Sevion Therapeutics Inc (Sevion), formerly Senesco Technologies, Inc. is a pharmaceutical company that discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company has developed protein nanocage system that allows delivery of nucleic …
  • Sumitomo Corporation (8053)-エネルギー分野:企業M&A・提携分析
    Summary Sumitomo Corporation (Sumitomo) is a multifaceted business enterprise. It operates various businesses such as metal products, transportation, construction systems, infrastructure, media, network & lifestyle retail, general products, real estate, financial services, logistics, mineral resourc …
  • Papyrus Australia Limited (PPY):企業の財務・戦略的SWOT分析
    Papyrus Australia Limited (PPY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • VSE Corporation (VSEC):企業の財務・戦略的SWOT分析
    VSE Corporation (VSEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Flex Ltd (FLEX):電力:M&Aディール及び事業提携情報
    Summary Flex Ltd (Flex) provides design, engineering, manufacturing, and supply chain services to electronics original equipment manufacturers. The company, through its Sketch-to-Scale concept, provides concept design, prototype creation, intellectual property protection, new product introduction, a …
  • Align Technology, Inc.:戦略・SWOT・企業財務分析
    Align Technology, Inc. - Strategy, SWOT and Corporate Finance Report Summary Align Technology, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Cheetah Medical Inc-医療機器分野:企業M&A・提携分析
    Summary Cheetah Medical Inc (Cheetah Medical) is a provider of non-invasive hemodynamic monitoring technologies. The company’s products comprise CHEETAH NICOM prewired sensors and Starling SV systems. It also offers Starling SV system accessories such as monitors and sensors, replacement parts, pole …
  • Steel Authority of India Ltd:企業の戦略・SWOT・財務情報
    Steel Authority of India Ltd - Strategy, SWOT and Corporate Finance Report Summary Steel Authority of India Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Stantec Inc (STN)-エネルギー分野:企業M&A・提携分析
    Summary Stantec Inc. (Stantec) is a consulting services company offering architectural, engineering, and environmental services. Its service portfolio includes architecture and interior design, building engineering, community design services, geomatics, geotechnical engineering, landscape architectu …
  • Telecom Egypt Company:企業の戦略・SWOT・財務分析
    Telecom Egypt Company - Strategy, SWOT and Corporate Finance Report Summary Telecom Egypt Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Eni SpA (ENI):企業の財務・戦略的SWOT分析
    Eni SpA (ENI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Mechel:企業のM&A・事業提携・投資動向
    Mechel - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mechel Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital rais …
  • Parenteral Drug India Ltd (PDPL):企業の財務・戦略的SWOT分析
    Summary Parenteral Drug India Ltd (PDIL) is a healthcare company that manufactures pharmaceutical products. The company provides products such as solid and liquid orals, IV fluids, oncology products and anaesthesia products. It offers IV fluids such as carbohyrated and electrolytes; diuretics, dialy …
  • Avid Technology Inc (AVID):企業の財務・戦略的SWOT分析
    Avid Technology Inc (AVID) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Covanta Holding Corporation
    Covanta Holding Corporation - Strategy, SWOT and Corporate Finance Report Summary Covanta Holding Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Cancer Genetics Inc (CGIX)-医療機器分野:企業M&A・提携分析
    Summary Cancer Genetics Inc (CGI) is a pharmaceutical company that offers diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic inform …
  • Valneva SE:企業のM&A・事業提携・投資動向
    Valneva SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Valneva SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆